Literature DB >> 15191698

Randomized clinical stroke trials in 2003.

Meheroz H Rabadi1, John Blass.   

Abstract

Randomized clinical stroke trials published during 2003 dealt with what impact treatment of stroke risk factors have on reducing future strokes. Treatment of hypertension and hyperlipidemia, and atrial fibrillation with a new anticoagulant, were confirmed to be beneficial. Treatment with female hormones was not beneficial. A potentially important study indicated that donepezil is a useful treatment for dementia in people who have had strokes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191698     DOI: 10.1007/s11883-004-0055-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  12 in total

1.  "Silent" strokes and dementia.

Authors:  John P Blass; Rajiv R Ratan
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

2.  Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.

Authors:  J B Segal; R L McNamara; M R Miller; N Kim; S N Goodman; N R Powe; K A Robinson; E B Bass
Journal:  J Gen Intern Med       Date:  2000-01       Impact factor: 5.128

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.

Authors:  Jordi Matías-Guiu; José M Ferro; José Alvarez-Sabín; Ferran Torres; M Dolores Jiménez; Aida Lago; Teresa Melo
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

5.  Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.

Authors:  Sandra Black; Gustavo C Román; David S Geldmacher; Stephen Salloway; Jane Hecker; Alistair Burns; Carlos Perdomo; Dinesh Kumar; Raymond Pratt
Journal:  Stroke       Date:  2003-09-11       Impact factor: 7.914

6.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

7.  The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Jürgen Berger; Walter Zidek; Johannes Treib; Karl Einhäupl; Hans Christoph Diener; Peter Dominiak
Journal:  Stroke       Date:  2003-06-19       Impact factor: 7.914

8.  Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.

Authors:  M Fransen; C Anderson; J Chalmers; N Chapman; S Davis; S MacMahon; B Neal; R Sega; A Terent; C Tzourio; M Woodward
Journal:  Stroke       Date:  2003-09-04       Impact factor: 7.914

9.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.